

**Supplemental Information Disclosure Statement**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: November 12, 2010 Signature: \_\_\_\_\_  
(Donna Dobson)

Docket No.: 51407/P029US/10605267  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
David J. Chapman-Jones

Application No.: 10/574,252

Confirmation No.: 9077

Filed: September 30, 2004

Art Unit: 3767

For: DRESSING FOR TISSUE TREATMENT

Examiner: S. D. Patel

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Commissioner:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the date of entry of the national stage of a PCT application, and after the mailing date of the first Office Action on the merits, but before the mailing date of any of a Final Office Action, a Notice of Allowance (37 CFR 1.97(c)) or an action that otherwise closes prosecution in the application.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents in accordance with 37 CFR 1.98(a)(2).

A translation is submitted herewith for the foreign patent reference RU-2090215-C1 listed on the attached PTO/SB/08. The translation was prepared by a Russian contact of the

assignee, Synapse Medical Solutions, Ltd., and was provided by the foreign associate who prosecuted United Kingdom patent application no. 0322851.7, which has been issued as patent no. UK 2406519, from which the present application claims priority. Applicant makes no claims as to the accuracy of the translation.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The fee of \$180.00 set forth in 37 CFR 1.17(p) will be paid by credit card. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2380, under Order No.  
51407/P029US/10605267.

Dated: November 12, 2010

Respectfully submitted,

By R. Ross Viguet  
R. Ross Viguet  
Registration No.: 42,203  
FULBRIGHT & JAWORSKI L.L.P.  
2200 Ross Avenue, Suite 2800  
Dallas, Texas 75201-2784  
(214) 855-8185  
(214) 855-8200 (Fax)  
Attorney for Applicant